Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Conformis

Request full access

Customized Partial & Total Knee Replacements

Billerica, United StatesFounded 2004Biotech & Life Sciences

About Conformis

Conformis, Inc. operates as a medical technology company, positioning itself at the intersection of advanced imaging and additive manufacturing to address the orthopedic joint replacement market. Founded in 2004 by Dr. Philipp Lang, a radiologist and professor with an M.D. and MBA, the company was born from his dissatisfaction with the limitations of standard, off-the-shelf implants. Lang's background in musculoskeletal radiology at institutions like Harvard Medical School and his experience in the medical device industry directly informed the company's core concept of making the implant fit the patient, not the other way around.

The company's business model centers on its proprietary iFit Image-to-Implant technology platform, which utilizes CT scans to create a 3D digital model of a patient's unique anatomy. This data-driven approach allows for the design and manufacture of individually sized and shaped joint replacement implants for knees and hips, along with patient-specific surgical instrumentation. This process aims to provide a more precise anatomical fit, preserve healthy bone, and simplify the surgical procedure for orthopedic surgeons. Revenue is generated through the sale of these personalized implant systems directly to hospitals and other healthcare facilities. The company serves a global market, with a sales presence in the United States, Europe, and Asia.

Conformis' product line includes a range of knee and hip replacement systems designed to treat conditions like osteoarthritis. Key offerings have included the iTotal CR (cruciate-retaining) and iTotal PS (posterior-stabilized) for total knee replacements, as well as partial knee solutions like the iUni and iDuo. The company also developed the Conformis Hip System. A significant milestone was the company's initial public offering (IPO) on July 7, 2015, trading on the NASDAQ under the symbol CFMS. Over its history, Conformis has secured numerous FDA 510(k) clearances for its products, starting with its iTotal system in 2011 and its hip system in 2017. Despite its technological advancements and having sold over 149,000 implants, the company faced financial struggles. In September 2023, Conformis was acquired by restor3d, a private medical device company specializing in 3D-printed orthopedic solutions. The acquisition combined restor3d's expertise with Conformis's established product lines and intellectual property, with the goal of creating a comprehensive personalized orthopedic device company.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2015

Conformis in the Billerica ecosystem

Live from Dealroom

The Conformis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Thorner Ventures

Series B and later9 investors entered at this stage

  • Industrial Bank of Taiwan
  • Merrill Lynch
  • Oxford Finance
  • CDIB BioScience Ventures
  • Calibrium
  • Axel Johnson
  • AGC EQUITY PARTNERS LIMITED
  • East West Bank
  • Innovatus Capital Partners
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Conformis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.